Company Interview / Argentica makes significant strides with a September update scheduled

Argenica Therapeutics (ASX: AGN) is making significant strides in acute neurological care with its lead candidate, ARG-007, a neuroprotective peptide aimed at reducing brain damage following stroke or injury. CEO Liz Dallimore states that Argenica has completed dosing in its phase two clinical trial, with a critical data readout expected in early September. The trial’s primary focus is assessing the safety of ARG-007, with regulatory requirements taking centre stage. Dallimore highlights the strategic addition of regulatory expert Sharon Graff to navigate complex global approval processes, including engagement with the FDA.

Dallimore notes that achieving a clear safety profile for ARG-007 will unlock further stages in drug development, including secondary endpoints assessing efficacy in reducing infarct volume post-stroke.

Argenica maintains a strong financial position, with $10.5 million in cash and no near-term plans to raise further capital. Dallimore indicates that strategic licensing or jurisdictional deals post-phase two could provide significant shareholder value and non-dilutive funding.

*The information contained in this event is general in nature and is not intended as advice. Before acting on information you've seen or heard at this event, you should seek professional financial advice which takes into account your personal circumstances. 

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD